0001658367-19-000001.txt : 20190321 0001658367-19-000001.hdr.sgml : 20190321 20190320182003 ACCESSION NUMBER: 0001658367-19-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190321 DATE AS OF CHANGE: 20190320 EFFECTIVENESS DATE: 20190321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ILIAD BIOTECHNOLOGIES, LLC CENTRAL INDEX KEY: 0001658367 IRS NUMBER: 454419429 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-328218 FILM NUMBER: 19695538 BUSINESS ADDRESS: STREET 1: 230 E 15TH STREET STREET 2: SUITE 1-A CITY: NEW YORK STATE: NY ZIP: 10003 BUSINESS PHONE: 917-913-8511 MAIL ADDRESS: STREET 1: 230 E 15TH STREET STREET 2: SUITE 1-A CITY: NEW YORK STATE: NY ZIP: 10003 D/A 1 primary_doc.xml X0708 D/A LIVE 0001658367 ILIAD BIOTECHNOLOGIES, LLC 4581 WESTON ROAD SUITE 260 WESTON FL FLORIDA 33331 917-913-8511 DELAWARE None None Limited Liability Company true KEITH RUBIN 4581 WESTON ROAD SUITE 260 WESTON FL FLORIDA 33331 Executive Officer Director KEN SOLOVAY 4581 WESTON ROAD SUITE 260 WESTON FL FLORIDA 33331 Executive Officer CUONG DO 4581 WESTON ROAD SUITE 260 WESTON FL FLORIDA 33331 Director BIN YAN 4581 WESTON ROAD SUITE 260 WESTON FL FLORIDA 33331 Director Biotechnology Decline to Disclose 06b true 0001658367-18-000003 true true true true false 0 WALTER C. GREENBLATT 4723413 WALTER GREENBLATT & ASSOCIATES 129291 327 ST. MARKS AVENUE BROOKLYN NY NEW YORK 11238 CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA PA PENNSYLVANIA TX TEXAS false 20000000 0 20000000 Total offering amount above excludes issuances to existing members pursuant to their preemptive rights in connection with this offering. false 0 1250000 true 0 Commission varies and can equal up to 8% of amount invested ($1.25MM assumes fully subscribed offering). Commission includes warrants to purchase units of the issuer (the value of such warrants on the issuance date is zero) 1750000 true The estimate assumes a fully subscribed offering and assumes awards of performance bonuses that are in the discretion of the issuer's board of managers. false ILIAD BIOTECHNOLOGIES, LLC /s/ Keith Rubin MD Keith Rubin CEO 2019-03-20